Fundz

Rhythm Metabolic, Inc. reported raising $25 Million in an initial SEC Form D filing, from an offering of $40 Million

PUBLIC · RYTMAug 12, 2015$25M of $40M raised

Amount Raised

$25 Million

$25 Million sold, per SEC Form D (first sale Aug 12, 2015)

Round Type

Venture

BostonBiotechnologyHealthcareHealth CareTherapeutics

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Rhythm Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Corvus Pharmaceuticals, Inc. raised $75M on September 25, 2015.
  • Wave Life Sciences raised $66M on August 28, 2015.
  • Ovid Therapeutics raised $75M on August 18, 2015.
  • CytoDyn raised $2M (Seed) on July 14, 2015.
  • Eximis Surgical raised $270K (Seed) on September 23, 2015.
  • TransMedics Group raised $500K on September 21, 2015.

Who to call at Rhythm Pharmaceuticals, and when

A new round usually means Rhythm Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Rhythm Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Rhythm Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Rhythm Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Rhythm Pharmaceuticals

Location

500 BOYLSTON STREET

Boston, Massachusetts, United States

About

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity caused by these diseases, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Rhythm Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Rhythm Pharmaceuticals's next move

See what Strategic adds

Rhythm Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.